Injections of botulinum toxin type A produce pain alleviation in intractable trigeminal neuralgia

被引:74
作者
Allam, N
Brasil-Neto, JP
Brown, G
Tomaz, C [1 ]
机构
[1] Univ Brasilia, Inst Biol, Dept Physiol Sci, BR-70910900 Brasilia, DF, Brazil
[2] Univ Brasilia, Grad Program Hlth Sci, BR-70910900 Brasilia, DF, Brazil
[3] Hosp Base Dist Fed, Neurol Unit, Brasilia, DF, Brazil
关键词
botulinum toxin; trigerminal neuralgia; pain alleviation;
D O I
10.1097/00002508-200503000-00010
中图分类号
R614 [麻醉学];
学科分类号
100217 [麻醉学];
摘要
To report the effects of local injections of botulinum toxin type A regarding pain relief and long-term control in a patient with intractable trigeminal neuralgia. The patient was a 75-year-old mail with trigeminal neuralgia in the left hemifacial region. His pain was unbearable and could not be controlled by carbamazepine, amitriptyline, or blocked by infiltration of a glycerol solution or phenol. The authors evaluated pain intensity, quality, and location Using a Visual Analog Scale to establish the efficacy of botulinum toxin type A injections. Two units of botulinum toxin type A (Botox(R)) were subcutaneously injected once in eight points distributed along the territory of V1 and V2. Visual Analog Scores were measured at baseline and at 7, 30, 60, and 90 days after treatment. The authors also examined the patient's general condition and daily life activities. The Visual Analog values were, respectively, 82, 54 25, 25, and 45 turn at each follow-up examination. No side effects were observed on the site of injection and on the patient's clinical state. The authors have been able to reduce trigeminal neuralgia pain with botulinum toxin type A injections in the V 1, V2 territory during all the period Of Study, as well as to withdraw all medication. Interestingly, there was concomitant reduction of pain also in V3, which was not injected.
引用
收藏
页码:182 / 184
页数:3
相关论文
共 32 条
[1]
TREATMENT OF MYOFASCIAL PAIN WITH BOTULINUM-A TOXIN [J].
ACQUADRO, MA ;
BORODIC, GE .
ANESTHESIOLOGY, 1994, 80 (03) :705-706
[2]
AOKI KR, 1998, PAIN DIGEST, V8, P337
[3]
Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial [J].
Barwood, S ;
Baillieu, C ;
Boyd, R ;
Brereton, K ;
Low, J ;
Nattrass, G ;
Graham, HK .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2000, 42 (02) :116-121
[4]
BENECKE R, 1975, PFLUGLERS ARCH, V359, P90
[5]
LOCALIZED INJECTIONS OF BOTULINUM TOXIN FOR THE TREATMENT OF FOCAL DYSTONIA AND HEMIFACIAL SPASM [J].
BRIN, MF ;
FAHN, S ;
MOSKOWITZ, C ;
FRIEDMAN, A ;
SHALE, HM ;
GREENE, PE ;
BLITZER, A ;
LIST, T ;
LANGE, D ;
LOVELACE, RE ;
MCMAHON, D .
MOVEMENT DISORDERS, 1987, 2 (04) :237-254
[6]
Das B, 2001, J Indian Med Assoc, V99, P704
[7]
FILLIPPI GM, 1993, ACTA OTOLARYNGOL STO, V113, P400
[8]
Botulinum toxin A and chronic low back pain - A randomized, double-blind study [J].
Foster, L ;
Clapp, L ;
Erickson, M ;
Jabbari, B .
NEUROLOGY, 2001, 56 (10) :1290-1293
[9]
The mechanism of action of Botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site [J].
Giladi, N .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 152 (02) :132-135
[10]
GOBEL H, 1999, MUNCH MED WSCHR, V139, P30